FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979574994> ?p ?o ?g. }

• W2979574994 endingPage "996" @default.
• W2979574994 startingPage "989" @default.
• W2979574994 abstract "•This study analyzes event rates of 2 high-potency statins in FH.•LDL-C goal attainment and risk were similar in both groups.•LDL-C reduction was greater with rosuvastatin. Events were similar in both groups.•Event rate was 1.1/100 patient-years with atorvastatin and 1.2 with rosuvastatin. BackgroundMaximal doses of potent statins are the basement of treatment of familial hypercholesterolemia (FH). Little is known about the use of different statin regimens in FH.ObjectivesThe objectives of the study were to describe the treatment changes and low-density lipoprotein cholesterol (LDL-C) goal achievement with atorvastatin (ATV) and rosuvastatin (RV) in the SAFEHEART cohort, as well as to analyze the incidence of atherosclerotic cardiovascular events (ACVEs) and changes in the cardiovascular risk.MethodsSAFEHEART is a prospective follow-up nationwide cohort study in a molecularly defined FH population. The patients were contacted on a yearly basis to obtain relevant changes in life habits, medication, and ACVEs.ResultsA total of 1939 patients were analyzed. Median follow-up was 6.6 years (5–10). The estimated 10-year risk according the SAFEHEART risk equation was 1.61 (0.67–3.39) and 1.22 (0.54–2.93) at enrollment for ATV and RV, respectively (P < .001). There were no significant differences at the follow-up: 1.29 (0.54–2.82) and 1.22 (0.54–2.76) in the ATV and RV groups, respectively (P = .51). Sixteen percent of patients in primary prevention with ATV and 18% with RV achieved an LDL-C <100 mg/dL and 4% in secondary prevention with ATV and 5% with RV achieved an LDL-C <70 mg/dL. The use of ezetimibe was marginally greater in the RV group. One hundred sixty ACVEs occurred during follow-up, being its incidence rate 1.1 events/100 patient-years in the ATV group and 1.2 in the RV group (P = .58).ConclusionATV and RV are 2 high-potency statins widely used in FH. Although the reduction in LDL-C levels was greater with RV than with ATV, the superiority of RV for reducing ACVEs was not demonstrated. Maximal doses of potent statins are the basement of treatment of familial hypercholesterolemia (FH). Little is known about the use of different statin regimens in FH. The objectives of the study were to describe the treatment changes and low-density lipoprotein cholesterol (LDL-C) goal achievement with atorvastatin (ATV) and rosuvastatin (RV) in the SAFEHEART cohort, as well as to analyze the incidence of atherosclerotic cardiovascular events (ACVEs) and changes in the cardiovascular risk. SAFEHEART is a prospective follow-up nationwide cohort study in a molecularly defined FH population. The patients were contacted on a yearly basis to obtain relevant changes in life habits, medication, and ACVEs. A total of 1939 patients were analyzed. Median follow-up was 6.6 years (5–10). The estimated 10-year risk according the SAFEHEART risk equation was 1.61 (0.67–3.39) and 1.22 (0.54–2.93) at enrollment for ATV and RV, respectively (P < .001). There were no significant differences at the follow-up: 1.29 (0.54–2.82) and 1.22 (0.54–2.76) in the ATV and RV groups, respectively (P = .51). Sixteen percent of patients in primary prevention with ATV and 18% with RV achieved an LDL-C <100 mg/dL and 4% in secondary prevention with ATV and 5% with RV achieved an LDL-C <70 mg/dL. The use of ezetimibe was marginally greater in the RV group. One hundred sixty ACVEs occurred during follow-up, being its incidence rate 1.1 events/100 patient-years in the ATV group and 1.2 in the RV group (P = .58). ATV and RV are 2 high-potency statins widely used in FH. Although the reduction in LDL-C levels was greater with RV than with ATV, the superiority of RV for reducing ACVEs was not demonstrated." @default.
• W2979574994 created "2019-10-18" @default.
• W2979574994 creator A5000628491 @default.
• W2979574994 creator A5002177930 @default.
• W2979574994 creator A5003971524 @default.
• W2979574994 creator A5015329406 @default.
• W2979574994 creator A5018981107 @default.
• W2979574994 creator A5032491154 @default.
• W2979574994 creator A5035352022 @default.
• W2979574994 creator A5047795094 @default.
• W2979574994 creator A5058100820 @default.
• W2979574994 creator A5059046557 @default.
• W2979574994 creator A5061870507 @default.
• W2979574994 creator A5064420882 @default.
• W2979574994 creator A5067752399 @default.
• W2979574994 creator A5070499961 @default.
• W2979574994 creator A5071279363 @default.
• W2979574994 creator A5072747894 @default.
• W2979574994 creator A5072866405 @default.
• W2979574994 creator A5074045003 @default.
• W2979574994 creator A5076996488 @default.
• W2979574994 creator A5079450462 @default.
• W2979574994 creator A5080022251 @default.
• W2979574994 creator A5080483751 @default.
• W2979574994 creator A5089419937 @default.
• W2979574994 creator A5090879464 @default.
• W2979574994 date "2019-11-01" @default.
• W2979574994 modified "2023-10-18" @default.
• W2979574994 title "Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study" @default.
• W2979574994 cites W1520609538 @default.
• W2979574994 cites W1844854928 @default.
• W2979574994 cites W2054455620 @default.
• W2979574994 cites W2105541785 @default.
• W2979574994 cites W2111099202 @default.
• W2979574994 cites W2127933204 @default.
• W2979574994 cites W2130760108 @default.
• W2979574994 cites W2133649500 @default.
• W2979574994 cites W2165624352 @default.
• W2979574994 cites W2272900183 @default.
• W2979574994 cites W2298508936 @default.
• W2979574994 cites W2405171365 @default.
• W2979574994 cites W2569910055 @default.
• W2979574994 cites W2587798296 @default.
• W2979574994 cites W2592111612 @default.
• W2979574994 cites W2605047128 @default.
• W2979574994 cites W2620146310 @default.
• W2979574994 cites W2743967130 @default.
• W2979574994 cites W2756164819 @default.
• W2979574994 cites W2894591464 @default.
• W2979574994 cites W2916492843 @default.
• W2979574994 cites W2920375683 @default.
• W2979574994 cites W2944448730 @default.
• W2979574994 cites W3129818723 @default.
• W2979574994 doi "https://doi.org/10.1016/j.jacl.2019.10.005" @default.
• W2979574994 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31706904" @default.
• W2979574994 hasPublicationYear "2019" @default.
• W2979574994 type Work @default.
• W2979574994 sameAs 2979574994 @default.
• W2979574994 citedByCount "27" @default.
• W2979574994 countsByYear W29795749942020 @default.
• W2979574994 countsByYear W29795749942021 @default.
• W2979574994 countsByYear W29795749942022 @default.
• W2979574994 countsByYear W29795749942023 @default.
• W2979574994 crossrefType "journal-article" @default.
• W2979574994 hasAuthorship W2979574994A5000628491 @default.
• W2979574994 hasAuthorship W2979574994A5002177930 @default.
• W2979574994 hasAuthorship W2979574994A5003971524 @default.
• W2979574994 hasAuthorship W2979574994A5015329406 @default.
• W2979574994 hasAuthorship W2979574994A5018981107 @default.
• W2979574994 hasAuthorship W2979574994A5032491154 @default.
• W2979574994 hasAuthorship W2979574994A5035352022 @default.
• W2979574994 hasAuthorship W2979574994A5047795094 @default.
• W2979574994 hasAuthorship W2979574994A5058100820 @default.
• W2979574994 hasAuthorship W2979574994A5059046557 @default.
• W2979574994 hasAuthorship W2979574994A5061870507 @default.
• W2979574994 hasAuthorship W2979574994A5064420882 @default.
• W2979574994 hasAuthorship W2979574994A5067752399 @default.
• W2979574994 hasAuthorship W2979574994A5070499961 @default.
• W2979574994 hasAuthorship W2979574994A5071279363 @default.
• W2979574994 hasAuthorship W2979574994A5072747894 @default.
• W2979574994 hasAuthorship W2979574994A5072866405 @default.
• W2979574994 hasAuthorship W2979574994A5074045003 @default.
• W2979574994 hasAuthorship W2979574994A5076996488 @default.
• W2979574994 hasAuthorship W2979574994A5079450462 @default.
• W2979574994 hasAuthorship W2979574994A5080022251 @default.
• W2979574994 hasAuthorship W2979574994A5080483751 @default.
• W2979574994 hasAuthorship W2979574994A5089419937 @default.
• W2979574994 hasAuthorship W2979574994A5090879464 @default.
• W2979574994 hasBestOaLocation W29795749941 @default.
• W2979574994 hasConcept C120665830 @default.
• W2979574994 hasConcept C121332964 @default.
• W2979574994 hasConcept C126322002 @default.
• W2979574994 hasConcept C188816634 @default.
• W2979574994 hasConcept C2776839432 @default.
• W2979574994 hasConcept C2777482532 @default.
• W2979574994 hasConcept C2778163477 @default.
• W2979574994 hasConcept C2779120738 @default.
• W2979574994 hasConcept C2780499067 @default.

• next